Drug Trial Radar · NCT07070349
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jul 10, 2025
Primary completion
Jan 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.
Conditions
- Patients With Solid Tumors
Interventions
HRS-6213Drug
HRS-6213 IV administered as imaging agent for PET scan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of adverse events (AEs) of HRS-6213Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)
- Phase 1: Radiation dosimetryTime frame: From first dose of study drug to end of treatment (up to approximately 7 days)
- Phase 2: With reference to the Standard of Truth (SOT), evaluate the diagnostic efficacy indicators of HRS-6213 PET at the lesion levelTime frame: rom first dose of study drug to end of treatment (up to approximately 60 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.